Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report.
R
R
Garg
C
C
Hussey
S
S
Ibrahim
D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D000077403:Orlistat; D010195:Pancreatitis / Q000139:chemically induced*; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use*
D019440:Anti-Obesity Agents; D004791:Enzyme Inhibitors; D007783:Lactones; D011719:Pyrazines; D014230:Triazoles; D000077403:Orlistat; D000068900:Sitagliptin Phosphate